LivaNova PLC Overview
Industry: Medical Devices
Sector: Healthcare
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. It also engages in research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom. LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary produc Read MoreMavefund brings filings, fundamentals, valuation, price history and news for LivaNova PLC into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $362.3M (+14.3% YoY); EPS was $0.4 (reported).
Revenue
$362.3M
+14.3% YoY
EPS
$0.4
reported
Operating income
$41.5M
reported
Free cash flow
$3.8M
reported
What changed
- Revenue +14.3% YoY to $362.3M; EPS reported to $0.4.
- Capital return update: free cash flow $3.8M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
May 06, 2026
SEC filing
8-K
May 06, 2026
SEC filing
10-K
Feb 25, 2026
SEC filing
8-K
Feb 25, 2026
Earnings release
Earnings release
Feb 25, 2026
SEC filing
8-K
Nov 05, 2025
Earnings release
Earnings release
Nov 05, 2025
SEC filing
10-Q
Nov 05, 2025
SEC filing
10-Q
Aug 06, 2025
Earnings release
Earnings release
Aug 06, 2025
SEC filing
8-K
Aug 06, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
LIVN270115C00065000 Interactive Stock Chart | LIVN Jan 2027 65.000 call Stock
Headline from Yahoo Finance: LIVN270115C00065000 Interactive Stock Chart | LIVN Jan 2027 65.000 call Stock.
Earnings Per Share
Score 4.00/5
LivaNova PLC boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Medical Devices industry
, Abbott Laboratories
, DexCom Inc
, Edwards Lifesciences Corp
are companies with high ratings.
Return on Equity
Score 2.06/5
LivaNova PLC exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 2.15/5
LivaNova PLC
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 2.07/5
LivaNova PLC
registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
have achieved high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios